Metacrine, Inc. (MTCR)

Market Cap	24.81M
Revenue (ttm)	n/a
Net Income (ttm)	-38.19M
Shares Out	43.83M
EPS (ttm)	-1.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,494
Open	0.575
Previous Close	0.567
Day's Range	0.566 - 0.575
52-Week Range	0.303 - 0.676
Beta	-0.77
Analysts	Sell
Price Target	0.51 (-9.89%)
Earnings Date	May 10, 2023

About MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 16, 2020
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: MTCR

Analyst Forecast

According to 7 analysts, the average rating for MTCR stock is "Sell." The 12-month stock price forecast is $0.51, which is a decrease of -9.89% from the latest price.

Price Target

$0.51

(-9.89% downside)

Analyst Consensus: Sell